Repligen | RGEN - Le Bénéfice D'Exploitation

Prix De L'Action
117.60
Variation Quotidienne
3.54 3.10%
Mensuellement
2.87%
Annuel
-18.76%
Q2 Prévisions
115.08




Le Bénéfice D'Exploitation Changement Date
Agilent USD 353M 90M 2025-12
Align Technology USD 224.71M 40.06M 2025-12
Bio Techne USD 54.46M 6.8M 2025-12
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Bruker USD 76.3M 7.6M 2025-12
Charles River Laboratories USD 75.82M 57.98M 2025-12
Danaher USD 1.34B 158M 2026-03
Dentsply International USD 538M 26M 2025-12
General Electric Aerospace USD 2.32B 549M 2026-03
Henry Schein USD 186M 12M 2025-12
Illumina USD 256M 6M 2025-12
IQVIA Holdings USD 2.68B 2.1B 2025-12
Mettler Toledo International USD 351.93M 57.73M 2025-12
Myriad Genetics USD -3M 20.3M 2025-12
OraSure Technologies USD -13.59M 2.13M 2025-12
Pacific Biosciences Of California USD -53.19M 35.08M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Repligen USD 19.97M 7.29M 2025-12
Revvity USD 145.83M 47.49M 2025-12
Standard Biotools USD -21.92M 1.55M 2025-12
Thermo Fisher Scientific USD 1.91B 389M 2026-03
Waters USD 270.52M 78.4M 2025-12
West Pharmaceutical Services USD 177.1M 14.6M 2026-03